Clinical Trials Happening
  Participants welcome
Donate to FRAXA
  You can help us find a cure
What is Fragile X?
Fragile X is the most common inherited cause of mental impairment and the most common known cause of autism.
About FRAXA
FRAXA is a 501c3 nonprofit run by parents. Our mission: to find treatments and a cure for Fragile X. FRAXA has funded over $22 million in research.
Visit our Blog
  families, researchers, trials
Email Signup
  Get the latest FRAXA News!

May 16, 2013

Seaside Therapeutics Discontinues Fragile X Clinical Trials of STX209 (arbaclofen)
Company cites financial constraints

read more >

May 02, 2013

Results of Phase 2b Clinical Trial of Arbaclofen in Autism Spectrum Disorder are Disappointing
Seaside Therapeutics reports the study did not show improvement on the primary endpoint of social withdrawal, but it did demonstrate improvement on the Clinical Global Impression of Severity scale.

read more >

March 20, 2013

Experimental compound FRAX486 Reverses Signs of Fragile X in mice
Another FRAXA-funded research grant has borne fruit, and an experimental new PAK inhibitor called FRAX486 is in the news.

read more >

March 18, 2013

FRAXA president & co-founder Katie Clapp on Diane Rehm Show
On Tuesday, 3/19, The Diane Rehm Show, a syndicated radio show, will discuss choosing efficient and effective charities.

read more >